What is PacGenomics?
PacGenomics operates as a sophisticated clinical laboratory infrastructure provider, specializing in the intersection of molecular diagnostics and precision medicine. The firm utilizes advanced technological modalities, including Next-Generation Sequencing (NGS) and Liquid Chromatography-Mass Spectrometry (LC-MS), to deliver high-fidelity analytical services. Their service portfolio is expansive, covering critical domains such as infectious disease diagnostics, clinical toxicology, and reproductive genetic testing. By maintaining rigorous quality control standards, PacGenomics serves as a vital partner for healthcare providers seeking actionable genetic insights and precise diagnostic data to improve patient outcomes across diverse clinical settings.
How much funding has PacGenomics raised?
PacGenomics has raised a total of $4.7M across 3 funding rounds:
Private Equity
$1.5M
Private Equity
$3M
Debt
$150K
Private Equity (2013): $1.5M, investors not publicly disclosed
Private Equity (2014): $3M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Key Investors in PacGenomics
PPP
Public-Private Partnership
Undisclosed Private Equity
A private equity firm focused on long-term value creation within the healthcare and life sciences sectors through strategic capital deployment.
Undisclosed Private Equity
An investment group specializing in late-stage funding rounds for established companies in the diagnostics and biotechnology space.
What's next for PacGenomics?
With the recent capital injection, PacGenomics is positioned to accelerate its market penetration and enhance its diagnostic throughput. The strategic focus will likely shift toward expanding its sequencing capabilities and integrating automated data processing workflows to meet the rising demand for personalized healthcare solutions. As the company matures, the emphasis on maintaining data integrity and operational excellence will be paramount in navigating the competitive landscape of clinical genomics. Future growth initiatives will likely involve scaling its laboratory footprint and potentially diversifying its diagnostic service offerings to address emerging challenges in infectious disease management and genetic screening, ensuring the firm remains at the forefront of the molecular diagnostics industry.
See full PacGenomics company page
